Androgen Deprivation Therapy Monitoring: A Canadian Population-based Study Exploring Evolving Adherence to Guidelines

Summary

Project ID: 2021-892 / TRIM 2023 0970 308 000

Principle Investigator: Christopher Wallis

Description: Androgen deprivation therapy (ADT) remains a part of the standard of care for men with advanced prostate cancer. The use of ADT has been associated with several side effects including osteopenia/osteoporosis, metabolic syndrome, and cardiovascular events. Men on ADT require frequent monitoring for the development of side effects which can subsequently be managed utilizing a variety of lifestyle and pharmaceutical interventions. Urologic associations including the CUA/AUA/EUA suggest regular monitoring of bone mineral density, serum calcium, serum lipids and plasma glucose levels for men throughout the duration of ADT. The project seeks to determine what is the adherence to CUA ADT therapeutic screening guidelines among Canadian men on ADT and has the adherence evolved over time?

PIA Approved: May 4, 2022